HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief: Bayer, NPA, FTC

This article was originally published in The Tan Sheet

Executive Summary

Dekkers gives Bayer two more years; Hilmas joins NPA; Hobbs directs Rainbow Light science; McSweeney starts at FTC; Bayer’s Mann takes WMSI chair; Archambault leads Ropack development.

You may also be interested in...



FDA Dietary Supplement Programs Research, Strategy Official Moves To NPA

Sibyl Swift is responsible for developing and implementing NPA's educational, regulatory and compliance programs such as SSCI and the NPA Natural Standard. She also will assist members with claim reviews, substantiation and NDI notification policy.

NPA Dusts Off DSHEA Coalition To Expand Industry’s Political Clout

NPA is restarting the Coalition to Preserve DSHEA on its own and other supplement industry trade groups are welcome to join. “We’re going to pick up the pace and really work to gain access the way other FDA-regulated industries do,” says NPA President Daniel Fabricant.

The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Topics

Related Companies

UsernamePublicRestriction

Register

RS139426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel